Cargando…
The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials
BACKGROUND: Dyslipidaemia is a major risk factor for coronary heart disease (CHD). Danhong and Huangqi injections, two traditional Chinese medicine prescriptions, have been widely studied regarding their lipid-lowering properties. However, the results were inconsistent and inconclusive. Thus, we con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944065/ https://www.ncbi.nlm.nih.gov/pubmed/29747663 http://dx.doi.org/10.1186/s12944-018-0760-2 |
_version_ | 1783321752787484672 |
---|---|
author | Yu, Liuqin Zhou, Chunyang Luo, Zhi Zeng, Wei Lai, Feiya Han, Gangjie Song, Yongyan |
author_facet | Yu, Liuqin Zhou, Chunyang Luo, Zhi Zeng, Wei Lai, Feiya Han, Gangjie Song, Yongyan |
author_sort | Yu, Liuqin |
collection | PubMed |
description | BACKGROUND: Dyslipidaemia is a major risk factor for coronary heart disease (CHD). Danhong and Huangqi injections, two traditional Chinese medicine prescriptions, have been widely studied regarding their lipid-lowering properties. However, the results were inconsistent and inconclusive. Thus, we conducted this meta-analysis of clinical controlled trials to clarify the lipid-lowering effects of Danhong and Huangqi injections. METHODS: The databases including PubMed, Google Scholar, Web of Science, Cochrane Library, Wanfang Database, CNKI and VIP were searched. The following information was obtained from each study: first author, age, gender, ethnicity, health condition, treatment dose, treatment duration, sample size, mean and standard deviation or standard error of lipid variables before and after treatment. The changes in lipid levels from pre- to post-treatment were calculated and compared between the control groups and the treatment groups in this meta-analysis. RESULTS: Forty-four studies (5021 subjects) and 7 studies (542 subjects) were respectively identified for Danhong and Huangqi injections. Compared with the control groups, Danhong injection yielded a significant reduction in triglycerides (TG) [standardized mean difference (SMD) = − 0.76, 95% confidence interval (CI) = (− 0.91, − 0.61), P < 0.001], total cholesterol (TC) [SMD = − 1.29, 95% CI = (− 1.56, − 1.03), P < 0.001] and low-density lipoprotein cholesterol (LDL-C) [SMD = − 0.76, 95% CI = (− 0.93, − 0.59), P < 0.001], and a significant elevation in high-density lipoprotein cholesterol (HDL-C) [SMD = 0.70, 95% CI = (0.41, 0.98), P < 0.001]. Regarding Huangqi injection, it yielded a significant reduction in TC [SMD = − 1.13, 95% CI = (− 2.09, − 0.16), P = 0.02] and marginally in TG [SMD = − 1.27, 95% CI = (− 2.53, 0.00), P = 0.05] comparing with the control groups. CONCLUSIONS: Danhong injection can effectively decrease the plasma levels of TG, TC and LDL-C, and increase HDL-C levels. Huangqi injection also has significant effects on TG and TC reduction, but not as powerful as Danhong injection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-018-0760-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5944065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59440652018-05-14 The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials Yu, Liuqin Zhou, Chunyang Luo, Zhi Zeng, Wei Lai, Feiya Han, Gangjie Song, Yongyan Lipids Health Dis Research BACKGROUND: Dyslipidaemia is a major risk factor for coronary heart disease (CHD). Danhong and Huangqi injections, two traditional Chinese medicine prescriptions, have been widely studied regarding their lipid-lowering properties. However, the results were inconsistent and inconclusive. Thus, we conducted this meta-analysis of clinical controlled trials to clarify the lipid-lowering effects of Danhong and Huangqi injections. METHODS: The databases including PubMed, Google Scholar, Web of Science, Cochrane Library, Wanfang Database, CNKI and VIP were searched. The following information was obtained from each study: first author, age, gender, ethnicity, health condition, treatment dose, treatment duration, sample size, mean and standard deviation or standard error of lipid variables before and after treatment. The changes in lipid levels from pre- to post-treatment were calculated and compared between the control groups and the treatment groups in this meta-analysis. RESULTS: Forty-four studies (5021 subjects) and 7 studies (542 subjects) were respectively identified for Danhong and Huangqi injections. Compared with the control groups, Danhong injection yielded a significant reduction in triglycerides (TG) [standardized mean difference (SMD) = − 0.76, 95% confidence interval (CI) = (− 0.91, − 0.61), P < 0.001], total cholesterol (TC) [SMD = − 1.29, 95% CI = (− 1.56, − 1.03), P < 0.001] and low-density lipoprotein cholesterol (LDL-C) [SMD = − 0.76, 95% CI = (− 0.93, − 0.59), P < 0.001], and a significant elevation in high-density lipoprotein cholesterol (HDL-C) [SMD = 0.70, 95% CI = (0.41, 0.98), P < 0.001]. Regarding Huangqi injection, it yielded a significant reduction in TC [SMD = − 1.13, 95% CI = (− 2.09, − 0.16), P = 0.02] and marginally in TG [SMD = − 1.27, 95% CI = (− 2.53, 0.00), P = 0.05] comparing with the control groups. CONCLUSIONS: Danhong injection can effectively decrease the plasma levels of TG, TC and LDL-C, and increase HDL-C levels. Huangqi injection also has significant effects on TG and TC reduction, but not as powerful as Danhong injection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12944-018-0760-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-10 /pmc/articles/PMC5944065/ /pubmed/29747663 http://dx.doi.org/10.1186/s12944-018-0760-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Yu, Liuqin Zhou, Chunyang Luo, Zhi Zeng, Wei Lai, Feiya Han, Gangjie Song, Yongyan The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title | The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title_full | The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title_fullStr | The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title_full_unstemmed | The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title_short | The lipid-lowering effects of Danhong and Huangqi injections: a meta-analysis of clinical controlled trials |
title_sort | lipid-lowering effects of danhong and huangqi injections: a meta-analysis of clinical controlled trials |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944065/ https://www.ncbi.nlm.nih.gov/pubmed/29747663 http://dx.doi.org/10.1186/s12944-018-0760-2 |
work_keys_str_mv | AT yuliuqin thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT zhouchunyang thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT luozhi thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT zengwei thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT laifeiya thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT hangangjie thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT songyongyan thelipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT yuliuqin lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT zhouchunyang lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT luozhi lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT zengwei lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT laifeiya lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT hangangjie lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials AT songyongyan lipidloweringeffectsofdanhongandhuangqiinjectionsametaanalysisofclinicalcontrolledtrials |